31st Mar 2008 10:31
Hutchison China Meditech Limited31 March 2008 Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) Holding in Company London, Monday, 31 March 2008: Chi-Med today announces that it receivednotification on 28 March 2008 that as at 27 March 2008, Lansdowne PartnersLimited Partnership controlled 3,440,000 shares in Chi-Med, representingapproximately 6.7% of the total issued shares of Chi-Med. These shares wereregistered under Morstan Nominees Limited, of which 3,284,492 shares were heldon behalf of Lansdowne UK Equity Fund Limited and 155,508 shares were held onbehalf of Lansdowne UK Equity Fund L.P. respectively. Ends Enquiries Chi-Med Telephone: +852 2121 8200 Christian Hogg, CEO Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571 Anthony Carlisle +44 (0) 7973 611 888 David Dible +44 (0) 7967 566 919 About Chi-Med Chi-Med is the holding company of a pharmaceutical and healthcare group focusedon traditional Chinese medicine ("TCM") based primarily in China and wasadmitted to trading on the Alternative Investment Market of the London StockExchange in May 2006. Chi-Med operates three core business segments: 1) Chinahealthcare - the manufacture, distribution and marketing of pharmaceuticals andhealth supplements in China; 2) Drug R&D - the discovery and global developmentof novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumerproducts - global retailing and distribution consumer health and personal careproducts derived from TCM and botanical ingredients. Chi-Med is majority owned by Hutchison Whampoa Limited, an international companylisted on the Main Board of The Stock Exchange of Hong Kong Limited. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hutchmed